ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IRMD vs SGP // EV/EBITDA & P/E VALUATION

iRadimed Corporation (NASDAQ) VS. SpyGlass Pharma Inc. (NASDAQ) • 15-METRIC TALLY: IRMD 5 — SGP 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRMD VS. SGP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IRMD SGP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 76.70% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 37.70% -35.00% +72.70 IRMD /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 31.9x — — TIE /valuation <GO>
Free Cash Flow Yield 1.57% -3.08% +4.65 IRMD /fcf-yield <GO>
Operating Margin 31.20% — — TIE /operating-margins <GO>
Net Profit Margin 26.80% — — TIE /net-margins <GO>
Revenue Growth (YoY) 14.40% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 1.37% 0.00% +1.37 IRMD /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 8/9 2/9 +6.00 IRMD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 25.6 71.4 -45.75 SGP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 41.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.10B $1.09B $9.0M IRMD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IRMD REV SGP REV IRMD GROSS % SGP GROSS % IRMD FCF SGP FCF
FY 2025 $83.8M $0 76.7% — $17.2M -$33.5M
FY 2024 $73.2M $0 76.9% — $17.6M -$24.0M
FY 2023 $65.6M — — — $13.5M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRMD // BETA —
SGP // BETA —